Publicacións en colaboración con investigadores/as de Harvard Medical School (4)

2023

  1. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Mutant IDH Inhibits IFNg–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

    Cancer Discovery, Vol. 12, Núm. 3, pp. 812-835

2021

  1. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma

    Immunity, Vol. 54, Núm. 3, pp. 571-585.e6

2019

  1. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

    Nature, Vol. 565, Núm. 7737, pp. 43-48